Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.61 |
| ▸ | CTSL | P07711 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213922 | 0.82 | BCL2 (0.61) | CTSKCTSLCTSSBCL2CTSB | |
| SCHEMBL22144261 | 0.81 | CTSK (0.66) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL265783 | 0.81 | CTSK (0.66) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL265461 | 0.81 | CTSK (0.66) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL329038 | 0.81 | CTSK (0.66) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL20381057 | 0.81 | CTSK (0.66) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL17123408 | 0.81 | CASP1 (0.53) | CTSKCTSLCTSSCASP1CA1 | |
| SCHEMBL15757065 | 0.80 | CTSK (0.65) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL22161320 | 0.80 | CTSK (0.65) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL15613297 | 0.80 | CTSK (0.65) | CTSKCTSLCTSSCTSBSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-1713822-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | CTSK 1317/4885CTSL 414/4885CTSS 391/4885 |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | CTSK 324/4885CTSL 48/4885CTSS 89/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | CTSK 546/4885CTSL 139/4885CTSS 152/4885 |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | CTSK 324/4885CTSL 48/4885CTSS 89/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | CTSK 289/4885CTSL 39/4885CTSS 69/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | CTSK 324/4885CTSL 48/4885CTSS 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.